Joshua T. Brumm, the Chief Executive Officer of Crescent Biopharma, Inc. (NASDAQ:CBIO), executed a significant transaction involving the sale of 42,305 ordinary shares on June 22, 2026. The aggregate proceeds from this divestment totaled approximately $761,066. The shares were disposed of at a weighted average price of $17.99 per share. The pricing for these individual transactions fluctuated within a range of $16.88 to $18.86 per share.
The current market price of the stock stands at $17.50. This valuation reflects a substantial 45% appreciation over the preceding six months and a 48% year-to-date return. Following the completion of these transactions, Mr. Brumm directly holds 281,212 ordinary shares of Crescent Biopharma. He continues to serve in his dual capacity as both a director and an officer of the biotech firm. The company carries a market capitalization of $585 million. According to InvestingPro analysis, CBIO appears slightly overvalued at current levels.
These sales were executed to satisfy tax withholding obligations associated with the settlement of restricted stock units. These units were granted to Mr. Brumm in December 2025 and March 2025. The transactions were carried out under a Rule 10b5-1 trading plan, which Mr. Brumm adopted on February 28, 2026. This plan was established specifically for covering taxes associated with the vesting of restricted stock units.
In other recent news, Crescent Biopharma Inc. has been in the spotlight following several developments. Cantor Fitzgerald reiterated an Overweight rating on the company after Pfizer announced that its Phase 3 trial for a competing drug did not meet its primary endpoint. Similarly, Stifel maintained a Buy rating and set a $30.00 price target, commenting on Pfizer's negative topline results from another Phase 3 trial. However, H.C. Wainwright downgraded Crescent Biopharma to Neutral from Buy, citing less compelling competitive positioning for its CR-001 candidate based on recent clinical data.
Additionally, Crescent Biopharma is set to present data from its ASCEND study at the 2026 American Society of Clinical Oncology Annual Meeting. This study is a global Phase 1/2 trial evaluating CR-001 in patients with various solid tumor types. The trial includes both treatment-naïve and previously treated patients. These recent developments provide investors with important insights into Crescent Biopharma's current standing in the market.